Envista (NYSE:NVST) PT Lowered to $19.00 at Robert W. Baird

Envista (NYSE:NVST) had its price target dropped by equities researchers at Robert W. Baird from $22.00 to $19.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price target suggests a potential downside of 3.80% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Morgan Stanley cut Envista from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $33.00 to $21.00 in a research note on Friday, April 26th. William Blair cut Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Leerink Partnrs reaffirmed an “underperform” rating on shares of Envista in a report on Monday, February 26th. TheStreet lowered Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. Finally, SVB Leerink started coverage on Envista in a report on Monday, February 26th. They set an “underperform” rating and a $19.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.09.

Envista Stock Performance

NVST stock opened at $19.75 on Thursday. The company has a current ratio of 2.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.33. The firm has a market cap of $3.39 billion, a P/E ratio of -32.38, a P/E/G ratio of 3.72 and a beta of 1.35. Envista has a 12-month low of $18.95 and a 12-month high of $38.43. The stock’s 50 day simple moving average is $20.80 and its 200 day simple moving average is $22.59.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The company had revenue of $645.60 million for the quarter, compared to the consensus estimate of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. Envista’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.52 earnings per share. As a group, equities research analysts predict that Envista will post 1.41 EPS for the current year.

Institutional Investors Weigh In On Envista

Several institutional investors have recently made changes to their positions in the company. Corbyn Investment Management Inc. MD increased its position in shares of Envista by 0.6% during the fourth quarter. Corbyn Investment Management Inc. MD now owns 73,899 shares of the company’s stock valued at $1,778,000 after purchasing an additional 462 shares during the period. Alliance Wealth Advisors LLC UT boosted its stake in Envista by 6.3% in the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 8,295 shares of the company’s stock valued at $231,000 after buying an additional 490 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in Envista by 0.6% in the 4th quarter. Wedge Capital Management L L P NC now owns 102,309 shares of the company’s stock valued at $2,462,000 after buying an additional 569 shares in the last quarter. Securian Asset Management Inc. boosted its stake in Envista by 4.3% in the 4th quarter. Securian Asset Management Inc. now owns 14,465 shares of the company’s stock valued at $348,000 after buying an additional 590 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after buying an additional 621 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.